Preference-based Comparative Study on Definitive Radiotherapy of Prostate Cancer With Protons
Launched by TECHNISCHE UNIVERSITÄT DRESDEN · May 9, 2016
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
The ProtoChoice-P trial is a study looking at a type of cancer treatment called proton therapy for men with prostate cancer. The main goal of the study is to see if using proton therapy can reduce the chances of experiencing moderate to severe side effects in the urinary or intestinal areas compared to traditional treatments. Researchers will also be examining other important factors, such as the quality of life after treatment, the chances of cancer coming back, overall survival rates, and the costs associated with proton versus traditional photon therapy.
To be eligible for this study, participants need to be men aged 65 to 74 with a specific type of prostate cancer called adenocarcinoma, which must not have spread to other parts of the body. They should be in good health and able to follow up with the study requirements. Participants will receive proton therapy and will be monitored over time to assess their health and quality of life. This trial is currently recruiting, so if you or a loved one are interested, it may be a great opportunity to explore a potentially beneficial treatment option.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • life expectancy ≥ 10 years
- • adenocarcinoma of the prostate confirmed by punch biopsy
- • locally limited to locally advanced adenocarcinomas without evidence of distant metastases i.e. T1-3b N0-1 M0
- • stage-related indicated neoadjuvant / adjuvant androgen deprivation possible (neoadjuvant ≤ 6 months)
- • good general condition (ECOG performance status 0 - 1)
- • marker seed implantation before irradiation (optional) or possibility of Image-guided Radiation Therapy (IGRT) by CT
- • adequate compliance for follow-up
- • written informed consent
- Exclusion Criteria:
- • distant metastases
- • previous radiotherapy of the lesser pelvis
- • previous or concomitant other malignant disease except when there is no impact on treatment or follow-up of the prostate cancer
- • participation in another clinical study, if it's excluded by the study protocols
About Technische Universität Dresden
Technische Universität Dresden (TU Dresden) is a leading research institution in Germany, renowned for its commitment to advancing scientific knowledge and innovation across various disciplines, including medicine and healthcare. As a clinical trial sponsor, TU Dresden leverages its cutting-edge research facilities and interdisciplinary expertise to facilitate the development of novel therapeutic interventions and improve patient outcomes. The university fosters collaboration among academic, clinical, and industry partners, ensuring rigorous adherence to ethical standards and regulatory requirements in the conduct of clinical research. Through its dedication to excellence and research-driven initiatives, TU Dresden plays a pivotal role in translating scientific discoveries into practical applications that benefit society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Munich, , Germany
Dresden, , Germany
Tubingen, , Germany
Patients applied
Trial Officials
Tobias Hölscher, Dr.
Study Chair
University Hospital Carl Gustav Carus, Department of Radiation Therapy and Radiation Oncology, German Consortium for Translational Cancer Research (DKTK)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials